Search results
Author(s):
Artemio García-Escobar
,
Juan Manuel Grande Ingelmo
Added:
3 years ago
To the Editor,
We congratulate Nadar and Shaikh for their excellent review of the use of biomarkers in heart failure (HF), as well as the new biomarkers currently under investigation.1
Red blood cell distribution width (RDW) is a measure of the heterogeneity of distribution of red blood cell size. A high RDW implies a large variation in red blood cell (RBC) size (anisocytosis) and a low RDW…
View more
Neprilysin as a Biomarker
Author(s):
Noemi Pavo
,
Suriya Prausmüller
,
Philipp E Bartko
,
et al
Added:
3 years ago
Article
Author(s):
Hans-Peter Brunner-La Rocca
,
Sema Bektas
Added:
3 years ago
Although the first study on biomarker-guided therapy of chronic heart failure (HF) was published 15 years ago,1 there is still no real proof of the superiority of this approach as compared with standard therapy. The guidelines of the European Society of Cardiology simply state that: “several RCTs that evaluated natriuretic peptide-guided treatment (intensifying treatment in order to lower peptide…
View more
Author(s):
Martin Moeckel
Added:
4 years ago
Prof Martin Mockel (Charité University, Berlin, DE) discusses biomarker guidance to start remote patient management in heart failure.
Filmed on site at HFA 2019 by Radcliffe Cardiology.
Videography: Mike Knight & Tom Green
Interviewer: Liam O'Neill
View more
Author(s):
Marko Kumric
,
Tina Ticinovic Kurir
,
Josko Bozic
,
et al
Added:
2 years ago
Author(s):
Sunil K Nadar
,
Muhammad Mujtaba Shaikh
Added:
3 years ago
Dear Editor,
We would like to thank García-Escobar and Ingelmo for their letter regarding our article on the use of biomarkers in routine clinical care for heart failure.1,2 It was with interest that we read their comments on the use of red cell volume distribution width (RDW) as another biomarker for use in the management of patients with heart failure. As mentioned in their letter, RDW is a…
View more
Added:
1 year ago
HRX 22 - GPX Inc. CEO Javier Echenique (GPX Inc., Boston, MA, US) joins us to discuss CardioID - a novel AI Algorithm-based "bloodless blood test" that uses NT-proBNP biomarkers in patient monitoring for heart failure decompensation. The TRIBE-HF 2 study is currently underway for algorithm training and validation.
Questions:
1. What are the clinical unmet needs in heart failure that led to the…
View more
James L Januzzi
Research Area(s) / Expertise:
Author
Expertise
Author(s):
Veronika Zach
,
Felix Lucas Bähr
,
Frank Edelmann
Added:
4 years ago
Heart failure (HF) is a chronic, progressive disease with steadily increasing incidence rates and high morbidity and mortality that represents a major challenge in healthcare worldwide.1–3 The disease is characterised by chronic exacerbations, recurrent hospitalisations and poor prognosis.1,2 Survival rates in HF patients are lower than in patients suffering from some malignant diseases,…
View more
Author(s):
Sunil K Nadar
,
Muhammad Mujtaba Shaikh
Added:
3 years ago
The National Institutes of Health Biomarkers Definitions Working Group define a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”.1 Biomarkers have become increasingly important in current medical practice as they offer an easy way to either…
View more